NEWSROOM | Galderma

Galderma’s phase III OLYMPIA 1 data published in JAMA Dermatology demonstrate that nemolizumab improves core signs and symptoms of prurigo nodularis

Celebrating 25 years of Sculptra®: new data and recent approval in China cements Galderma’s leadership in regenerative biostimulation

Galderma brings together over 650 healthcare professionals from Asia-Pacific to elevate knowledge of future aesthetic trends

Galderma delivers record net sales of 3.259 B USD in the first nine months of 2024, demonstrates significant innovation progress, confirms and narrows its full year net sales guidance

ASDS 2024: new phase III READY-4 data demonstrate long-term safety and efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)

ASDS 2024: Galderma presents data on RelabotulinumtoxinA and Sculptra®

EADV 2024 Late breaking news sessions: new Galderma data demonstrating nemolizumab’s long-term efficacy and safety in atopic dermatitis and durability in prurigo nodularis to be shared during three oral presentations

EADV 2024: scientific presentations supported by Galderma

Galderma reaffirms its leadership in dermatology with extensive presence at EADV 2024

Identifying unmet patient needs on World Atopic Eczema Day

Galderma launches Cetaphil Gentle Exfoliating line with Gen-Z it-girl Katie Fang

Galderma successfully issued an inaugural CHF 500 million bond

Galderma receives U.S. FDA approval for Nemluvio® (nemolizumab) for adult patients living with prurigo nodularis